loader
Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of Inotersen reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Inotersen

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 1TEGSEDI and WAYLIVRA revenue, net

    02 3Tegsedi

    03 2Tegsedi and Waylivra Revenue, Net

    PharmaCompass
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Tegsedi

    Inotersen

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Tegsedi

    Sweden
    arrow
    Luxepack
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Inotersen

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2021 Revenue in Millions : 46

    2020 Revenue in Millions : 0

    Growth (%) : 100

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : TEGSEDI and WAYLIVRA revenue, net

    Inotersen

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : TEGSEDI and WAYLIVRA revenue, net

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Ionis Pharmaceuticals

    Inotersen

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2021 Revenue in Millions : 56

    2020 Revenue in Millions : 70

    Growth (%) : -21

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Tegsedi and Waylivra Revenue, Net

    Inotersen

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Tegsedi and Waylivra Revenue, Net

    U.S.A
    arrow
    Luxepack
    Not Confirmed

    Ionis Pharmaceuticals

    Inotersen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2022 Revenue in Millions : 30

    2021 Revenue in Millions : 56

    Growth (%) : -46

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Tegsedi and Waylivra Revenue, Net

    Inotersen

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Tegsedi and Waylivra Revenue, Net

    U.S.A
    arrow
    Luxepack
    Not Confirmed

    Ionis Pharmaceuticals

    Inotersen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2023 Revenue in Millions : 35

    2022 Revenue in Millions : 30

    Growth (%) : 16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Tegsedi

    Inotersen

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Tegsedi

    Sweden
    arrow
    Luxepack
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Inotersen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2022 Revenue in Millions : 40

    2021 Revenue in Millions : 46

    Growth (%) : -12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Tegsedi

    Inotersen

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Tegsedi

    Sweden
    arrow
    Luxepack
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Inotersen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2023 Revenue in Millions : 29

    2022 Revenue in Millions : 40

    Growth (%) : -29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF